心泰医疗2023中期报告

Stock Code 股份代號 : 2291 Contents Definitions2Corporate Information7Financial Highlights10Management Discussion and Analysis11Other Information39Report on Review of46Interim Financial InformationInterim Condensed Consolidated48Statement of Profit or Loss andOther Comprehensive IncomeInterim Condensed Consolidated49Balance SheetInterim Condensed Consolidated51Statement of Changes in EquityInterim Condensed Consolidated52Statement of Cash FlowsNotes to the Interim Condensed54Consolidated Financial Information27101139464849515254 Definitions In this report, the following expressions have the meanings setout below unless the context requires otherwise: Definitions Definitions Corporate Information BOARD OF DIRECTORS Executive Directors Ms. Chen Juan(Chairman)Ms. Zhang Yuxin Non-Executive Directors Mr. Fu ShanMr. Zheng Guorui Independent Non-Executive Directors Ms. Chan Ka Lai VanessaMr. Zheng YufengMr. Liu Daozhi SUPERVISORS Mr. Wang XinglinMs. Wang XiaoyongMr. Qian Weidong AUDIT COMMITTEE Ms. Chan Ka Lai Vanessa(Chairperson)Mr. Zheng GuoruiMr. Zheng Yufeng REMUNERATION COMMITTEE Mr. Zheng Yufeng(Chairperson)Ms. Chen JuanMr. Fu ShanMs. Chan Ka Lai VanessaMr. Liu Daozhi NOMINATION COMMITTEE Ms. Chen Juan(Chairperson)Mr. Zheng GuoruiMs. Chan Ka Lai VanessaMr. Zheng YufengMr. Liu Daozhi Corporate Information JOINT COMPANY SECRETARIES 20237 1820237 18 Mr. Qin XueMs. Ko Mei Ying(appointed on 18 July 2023)Ms. Ng Ka Man(resigned on 18 July 2023) AUTHORIZED REPRESENTATIVES Ms. Chen JuanMs. Zhang Yuxin ALTERNATE AUTHORISED REPRESENTATIVE 20237 18 Ms. Ko Mei Ying(appointed on 18 July 2023) LEGAL ADDRESS IN THE PRC 25841201 Room 201Building 41No. 258, Xinzhuan RoadSongjiang DistrictShanghaiPRC ADDRESS OF HEAD OFFICE IN THE PRC 2584115 1/F, 5/FBuilding 41No. 258, Xinzhuan RoadSongjiang DistrictShanghaiPRC PRINCIPAL PLACE OF BUSINESS IN HONGKONG 3485 5/F, Manulife Place348 Kwun Tong RoadKowloonHong Kong AUDITOR 22 PricewaterhouseCoopersCertified Public Accountants andRegistered Public Interest Entity Auditor22/F, Prince’s BuildingCentralHong Kong Corporate Information LEGAL ADVISORS As to Hong Kong lawWilson Sonsini Goodrich & Rosati ••• As to PRC lawHaiwen & Partners COMPLIANCE ADVISOR 811 Halcyon Capital Limited11/F, 8 Wyndham StreetCentralHong Kong HONG KONG SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong PRINCIPAL BANKS Bank of ShanghaiChina Merchants BankIndustrial and Commercial Bank of ChinaBank of Ningbo http://www.scientechmed.com/ COMPANY WEBSITE http://www.scientechmed.com/ 2022118 LISTING DATE November 8, 2022 STOCK CODE 2291 2291 Financial Highlights 2022630124.833.0%2023630165.9 –Revenue increased by 33.0% from RMB124.8 million forthe six months ended June 30, 2022 to RMB165.9 millionfor the six months ended June 30, 2023. 2022630109.534.8%2023630147.5 –Gross profit increased by 34.8% from RMB109.5 millionfor the six months ended June 30, 2022 to RMB147.5million for the six months ended June 30, 2023. 2 0 2 263 019.636.5%202363026.8 –Research and development expenses increased by 36.5%from RMB19.6 million for the six months ended June 30,2022 to RMB26.8 million for the six months ended June30, 2023. –Net other income (net of other income and other gains/losses) of RMB5.0 million for the six months ended June30, 2023 was recorded compared to a net other losses(net of other income and other gains/losses) of RMB18.3million for the six months ended June 30, 2022. 20236305.0202263018.3 202263024.3213.7%202363076.1 –Profit attributable to owners of the Company increased by213.7% from RMB24.3 million for the six months endedJune30,2022 to RMB76.1 million for the six monthsended June 30, 2023. 202363086.5 –Thenon-IFRS Adjusted Net Profit for the six monthsended June 30, 2023 was RMB86.5 million. Management Discussion and Analysis BUSINESS REVIEW Asa pioneer in the structural heart disease interventionalmedicaldevices industry in China and a domestic leadingsupplier of medical devices, such as CHD occluders, we havebeen focusing on the research and development, manufactureand commercialization of structural heart disease interventionalmedicaldevices,and have also expanded into the cardiacmechanicalcirculatory support and other medical devicesfrontier fields, and are committed to providing safe, effective,innovative and comprehensive medical solutions. 20827 As of the date of this report, we had a total of 20 marketedo c c l u d e r sa n d a c c e s s o r y p r o d u c t s ,8 p r o d u c t s u n d e rregistrationreview and preparation for registration,and27product candidates in various stages of research anddevelopment such as occluders, heart valves and proceduralaccessories and mechanical circulatory support. The followingchartsummarizes the development status of our productportfolio up to the date of this report: Management Discussion and Analysis Management Discussion and Ana